Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB26FX1KM
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,509
Award facts
- Contract value 100% obligated
- $19,508.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,508.97 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Tecentriq (1,200 mg/20 ml vial). This delivery order, issued on October 28, 2025, with an ultimate completion date of November 19, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group Inc. is registered in the System for Award Management and maintains a longstanding federal contracting presence since July 2001, specializing in distributing comprehensive pharmaceutical products and medical consumables to Department of Defense facilities.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide recurring pharmaceutical supplies to military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. Under this framework, DMS Pharmaceutical Group serves as a critical regional prime vendor contractor authorized to fulfill diverse and specialized pharmaceutical requirements, including branded and generic prescription drugs, biologics, and medical consumables, for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FX1KM?
SPE2DB26FX1KM was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DB26FX1KM worth?
The government has obligated $19,509 on SPE2DB26FX1KM.
Is contract SPE2DB26FX1KM an order under another contract?
Yes. SPE2DB26FX1KM is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1KM competed?
The extent of competition for SPE2DB26FX1KM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award